泰凌医药(01011) - 2024 - 年度业绩

Supplementary Announcement Regarding Termination of Very Substantial Acquisition and 2023 Annual Report Subsequent Arrangements for Termination of Very Substantial Acquisition Company terminated a substantial acquisition, securing 473 million consideration shares with a 24-month lock-up, and began a new three-year orthopedic collaboration - As part of the acquisition advisory agreement, the company issued 473,186,591 consideration shares to an independent consultant[3] - To protect company interests, a 24-month lock-up arrangement was imposed on the aforementioned consideration shares, restricting the consultant from selling or disposing of them[3] - Following the acquisition termination, the company and the consultant entered a new three-year cooperation agreement for global research into innovative orthopedic medical devices and drugs, with no additional cost to the company[4] Accounting Treatment and Justification for Intangible Assets Company did not recognize intangible assets from terminated acquisition in 2023 report, citing invalid valuation assumptions due to macro changes, industry decline, drug price pressure, and project issues Reasons for Invalidity of Original Valuation Assumptions Original intangible asset valuation assumptions are invalid due to US Biosecurity Act risks, biopharma decline, China drug price cuts, sample technical issues, and project approval delays Key Factors Leading to Invalidity of Original Valuation Assumptions | Category | Specific Content | | :--- | :--- | | Policy and Macro Environment | US Biosecurity Act draft may restrict clinical trial data transfer; severe recession in the biopharmaceutical industry in 2023; China's national medical insurance drug catalog system driving down prices for innovative drugs | | Technical and Progress Issues | Clinical trials not yet started, samples have technical issues (increased impurities) affecting product quality stability; project approval delayed until after 2026, with an uncertain timeline | Justification for Non-Recognition of Intangible Assets in Financial Statements Company did not recognize related items as intangible assets in 2023 report, citing project incompleteness, sample technical issues, unpaid $2M initial payment, and termination risk - The four core reasons for the company's non-recognition of intangible assets are: - The project is far from completion - Samples have technical issues - The initial payment of $2 million to the licensor has not yet been made - The project carries inherent termination risk[6]